지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
이용수
초록· 키워드
오류제보하기
Purpose: The purpose of this study is to assess appropriateness of current standard for insurance coverage by Health Insurance Review & Assessment Service (HIRA) on chemotherapy used in the treatment of advanced non-small cell lung cancer (NSCLC), by reviewing a variety of clinical evidences, and thereby, if needed, to propose an updated evidence-based recommendations.
Methods: We collected data from HIRA regarding on the insurance standard which includes the scope and conditions for coverage on systemic chemotherapy of NSCLC. We performed a search for clinical databases and examined the most current clinical evidence from clinical literature including various clinical practice guidelines. Based on the collected data the appropriateness of HIRA standard for insurance coverage of chemotherapy of NSCLC was assessed.
Results: Collected data demonstrated that HIRA standard did not reflect the most current clinical practice and evidence.
Some were inappropriately listed in HIRA formulary and accepted as a chemotherapy being covered by insurance,despite the lack of evidences of clinical efficacy or superiority over other chemotherapeutic agents or regimens. In addition, there seems to be a need for a modification on the standard for insurance coverage of certain newer chemotherapeutic agents based on the current accumulated data showing their clinical efficacy and benefits in the selected group of NSCLC patients. Therefore, we concluded that current HIRA standard for insurance coverage on chemotherapy of NSCLC needs to be revised and we proposed an updated recommendation based on these latest clinical evidences.
Conclusion: The standard for insurance coverage of chemotherapy should be continually examined its appropriateness based on the most recent clinical evidences in a timely manner so as to provide the most effective and safe therapy to cancer patients.
목차
등록된 정보가 없습니다.
참고문헌 (23)
참고문헌 신청
/ / GLOBOCAN 2008. Cancer incidence and mortality worldwide in 2008
Alberts WM / 2007 / Diagnosis and management of lung cancer executive summary: ACCP evidence-based clinical practice guidelines (2nd Edition) / Chest 132 : 1S ~ 19S
Ardizzoni A / 2007 / Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysi
Azzoli CG / 2009 / American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer / J Clin Oncol 27 : 6251
D'Addario G / 2005 / Platinum-based versus non-platinum-based chemotherapy in advanced nonsmall- cell lung cancer: A meta-analysis of the published literature / J Clin Oncol
Alberts WM / 2007 / Diagnosis and management of lung cancer executive summary: ACCP evidence-based clinical practice guidelines (2nd Edition) / Chest 132 : 1S ~ 19S
Ardizzoni A / 2007 / Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysi
Azzoli CG / 2009 / American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer / J Clin Oncol 27 : 6251
D'Addario G / 2005 / Platinum-based versus non-platinum-based chemotherapy in advanced nonsmall- cell lung cancer: A meta-analysis of the published literature / J Clin Oncol
이 논문의 저자 정보
최근 본 자료
댓글(0)
0